Patients with resected stage IIIB-C or stage IV melanoma had better long-term outcomes with nivolumab vs ipilimumab.
A UK study shows a high discrepancy in the treatment costs between early- and late-stage melanomas, highlighting the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback